Cargando…

Long-term myocardial functional improvement after autologous bone marrow mononuclear cells transplantation in patients with ST-segment elevation myocardial infarction: 4 years follow-up‡

AIMS: To evaluate the safety profile and efficacy of bone marrow mononuclear cells (BMMNC) transplantation for ST-segment elevation myocardial infarction (STEMI) by assessing patients and their left ventricular function at up to 4 years follow-up. METHODS AND RESULTS: Eighty-six patients with STEMI...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Feng, Sun, Dongdong, Li, Chengxiang, Narsinh, Kazim, Zhao, Li, Li, Xue, Feng, Xuyang, Zhang, Jun, Duan, Yunyan, Wang, Jing, Liu, Dingjing, Wang, Haichang
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726958/
https://www.ncbi.nlm.nih.gov/pubmed/19508995
http://dx.doi.org/10.1093/eurheartj/ehp220
_version_ 1782170645629501440
author Cao, Feng
Sun, Dongdong
Li, Chengxiang
Narsinh, Kazim
Zhao, Li
Li, Xue
Feng, Xuyang
Zhang, Jun
Duan, Yunyan
Wang, Jing
Liu, Dingjing
Wang, Haichang
author_facet Cao, Feng
Sun, Dongdong
Li, Chengxiang
Narsinh, Kazim
Zhao, Li
Li, Xue
Feng, Xuyang
Zhang, Jun
Duan, Yunyan
Wang, Jing
Liu, Dingjing
Wang, Haichang
author_sort Cao, Feng
collection PubMed
description AIMS: To evaluate the safety profile and efficacy of bone marrow mononuclear cells (BMMNC) transplantation for ST-segment elevation myocardial infarction (STEMI) by assessing patients and their left ventricular function at up to 4 years follow-up. METHODS AND RESULTS: Eighty-six patients with STEMI who had successfully undergone percutaneous coronary intervention (PCI) were randomized to receive intracoronary injection of BMMNC (n = 41) or saline (n = 45). Left ventricular ejection fraction, as evaluated by UCG, was markedly improved at 6 months (0.484 ± 0.5 vs. 0.457 ± 0.6, P = 0.001), 1 year (0.482 ± 0.7 vs. 0.446 ± 0.6, P < 0.001), and 4 years (0.505 ± 0.8 vs. 0.464 ± 0.8, P < 0.001) after BMMNC transplant when compared with control group. However, the current cell therapy did not improve the myocardial viability of the infarcted area as assessed by single-photon emission computed tomography analysis at 4 years post-transplant (0.263 ± 0.007 in BMMNC group vs. 0.281 ± 0.008 in control group, P = 0.10). During the follow-up period, one control group case (2.2%) of in-stent restenosis was confirmed by coronary angiography and underwent repeat PCI. Also during follow-up, one death (2.2%) occurred in the control group, and one patient (2.4%) in the BMMNC group had transient acute heart failure. CONCLUSION: This study indicates that intracoronary delivery of autologous BMMNC is safe and feasible for STEMI patients who have undergone PCI, and can lead to long-term improvement in myocardial function.
format Text
id pubmed-2726958
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-27269582009-08-20 Long-term myocardial functional improvement after autologous bone marrow mononuclear cells transplantation in patients with ST-segment elevation myocardial infarction: 4 years follow-up‡ Cao, Feng Sun, Dongdong Li, Chengxiang Narsinh, Kazim Zhao, Li Li, Xue Feng, Xuyang Zhang, Jun Duan, Yunyan Wang, Jing Liu, Dingjing Wang, Haichang Eur Heart J Clinical Research AIMS: To evaluate the safety profile and efficacy of bone marrow mononuclear cells (BMMNC) transplantation for ST-segment elevation myocardial infarction (STEMI) by assessing patients and their left ventricular function at up to 4 years follow-up. METHODS AND RESULTS: Eighty-six patients with STEMI who had successfully undergone percutaneous coronary intervention (PCI) were randomized to receive intracoronary injection of BMMNC (n = 41) or saline (n = 45). Left ventricular ejection fraction, as evaluated by UCG, was markedly improved at 6 months (0.484 ± 0.5 vs. 0.457 ± 0.6, P = 0.001), 1 year (0.482 ± 0.7 vs. 0.446 ± 0.6, P < 0.001), and 4 years (0.505 ± 0.8 vs. 0.464 ± 0.8, P < 0.001) after BMMNC transplant when compared with control group. However, the current cell therapy did not improve the myocardial viability of the infarcted area as assessed by single-photon emission computed tomography analysis at 4 years post-transplant (0.263 ± 0.007 in BMMNC group vs. 0.281 ± 0.008 in control group, P = 0.10). During the follow-up period, one control group case (2.2%) of in-stent restenosis was confirmed by coronary angiography and underwent repeat PCI. Also during follow-up, one death (2.2%) occurred in the control group, and one patient (2.4%) in the BMMNC group had transient acute heart failure. CONCLUSION: This study indicates that intracoronary delivery of autologous BMMNC is safe and feasible for STEMI patients who have undergone PCI, and can lead to long-term improvement in myocardial function. Oxford University Press 2009-08 2009-06-09 /pmc/articles/PMC2726958/ /pubmed/19508995 http://dx.doi.org/10.1093/eurheartj/ehp220 Text en Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org http://creativecommons.org/licenses/by-nc/2.0/uk/ The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that the original authorship is properly and fully attributed; the Journal, Learned Society and Oxford University Press are attributed as the original place of publication with correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org
spellingShingle Clinical Research
Cao, Feng
Sun, Dongdong
Li, Chengxiang
Narsinh, Kazim
Zhao, Li
Li, Xue
Feng, Xuyang
Zhang, Jun
Duan, Yunyan
Wang, Jing
Liu, Dingjing
Wang, Haichang
Long-term myocardial functional improvement after autologous bone marrow mononuclear cells transplantation in patients with ST-segment elevation myocardial infarction: 4 years follow-up‡
title Long-term myocardial functional improvement after autologous bone marrow mononuclear cells transplantation in patients with ST-segment elevation myocardial infarction: 4 years follow-up‡
title_full Long-term myocardial functional improvement after autologous bone marrow mononuclear cells transplantation in patients with ST-segment elevation myocardial infarction: 4 years follow-up‡
title_fullStr Long-term myocardial functional improvement after autologous bone marrow mononuclear cells transplantation in patients with ST-segment elevation myocardial infarction: 4 years follow-up‡
title_full_unstemmed Long-term myocardial functional improvement after autologous bone marrow mononuclear cells transplantation in patients with ST-segment elevation myocardial infarction: 4 years follow-up‡
title_short Long-term myocardial functional improvement after autologous bone marrow mononuclear cells transplantation in patients with ST-segment elevation myocardial infarction: 4 years follow-up‡
title_sort long-term myocardial functional improvement after autologous bone marrow mononuclear cells transplantation in patients with st-segment elevation myocardial infarction: 4 years follow-up‡
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726958/
https://www.ncbi.nlm.nih.gov/pubmed/19508995
http://dx.doi.org/10.1093/eurheartj/ehp220
work_keys_str_mv AT caofeng longtermmyocardialfunctionalimprovementafterautologousbonemarrowmononuclearcellstransplantationinpatientswithstsegmentelevationmyocardialinfarction4yearsfollowup
AT sundongdong longtermmyocardialfunctionalimprovementafterautologousbonemarrowmononuclearcellstransplantationinpatientswithstsegmentelevationmyocardialinfarction4yearsfollowup
AT lichengxiang longtermmyocardialfunctionalimprovementafterautologousbonemarrowmononuclearcellstransplantationinpatientswithstsegmentelevationmyocardialinfarction4yearsfollowup
AT narsinhkazim longtermmyocardialfunctionalimprovementafterautologousbonemarrowmononuclearcellstransplantationinpatientswithstsegmentelevationmyocardialinfarction4yearsfollowup
AT zhaoli longtermmyocardialfunctionalimprovementafterautologousbonemarrowmononuclearcellstransplantationinpatientswithstsegmentelevationmyocardialinfarction4yearsfollowup
AT lixue longtermmyocardialfunctionalimprovementafterautologousbonemarrowmononuclearcellstransplantationinpatientswithstsegmentelevationmyocardialinfarction4yearsfollowup
AT fengxuyang longtermmyocardialfunctionalimprovementafterautologousbonemarrowmononuclearcellstransplantationinpatientswithstsegmentelevationmyocardialinfarction4yearsfollowup
AT zhangjun longtermmyocardialfunctionalimprovementafterautologousbonemarrowmononuclearcellstransplantationinpatientswithstsegmentelevationmyocardialinfarction4yearsfollowup
AT duanyunyan longtermmyocardialfunctionalimprovementafterautologousbonemarrowmononuclearcellstransplantationinpatientswithstsegmentelevationmyocardialinfarction4yearsfollowup
AT wangjing longtermmyocardialfunctionalimprovementafterautologousbonemarrowmononuclearcellstransplantationinpatientswithstsegmentelevationmyocardialinfarction4yearsfollowup
AT liudingjing longtermmyocardialfunctionalimprovementafterautologousbonemarrowmononuclearcellstransplantationinpatientswithstsegmentelevationmyocardialinfarction4yearsfollowup
AT wanghaichang longtermmyocardialfunctionalimprovementafterautologousbonemarrowmononuclearcellstransplantationinpatientswithstsegmentelevationmyocardialinfarction4yearsfollowup